mainstay

Mainstay Medical announces € 30 million fundraising

on 17/06/2016 12:43
New capital to support European Commercialisation and US PMA clinical trial
Read more

Mainstay Medical full year 2015 preliminary results and business update

on 16/02/2016 14:15

Additional data confirm positive results for Clinical Trial of ReActiv8®

on 04/12/2015 10:24
Additional data confirm clinically important, statistically significant, and lasting improvement in pain, disability, and quality of life for people with Chronic Low Back Pain and limited treatment options
Read more

Mainstay Medical – Interim Management Statement

on 09/11/2015 11:45

Mainstay Medical Applies for CE Mark for ReActiv8®

on 02/11/2015 11:38
A key step towards European commercialisation of innovative treatment of chronic low back pain
Read more